Company news
Beyondspring, Inc. (NASDAQ:BYSI) news
Every Beyondspring, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
August 14, 2026
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
June 4, 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Doceta...
June 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 18, 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
April 22, 2026
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
March 30, 2026
BeyondSpring Reports 2025 Year-End Financial Results
March 25, 2026
BeyondSpring Files 2025 Annual Report on Form 10-K
March 25, 2026
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
February 9, 2026
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGF...
December 12, 2025
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for...
December 11, 2025
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Ad...
August 13, 2025
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response Af...
July 7, 2025
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Prog...
June 3, 2025
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
May 28, 2025
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
BeyondSpring Files 2024 Annual Report on Form 10-K
March 27, 2025
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
March 27, 2025
BeyondSpring : 2024 Full Year Financial Report
March 26, 2025
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-C...
January 28, 2025
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in ...
November 11, 2024
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
September 16, 2024
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing...
September 10, 2024
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 20...
September 3, 2024
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
May 16, 2024
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
May 3, 2024
BeyondSpring Files 2023 Annual Report on Form 20-F
April 29, 2024
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
April 29, 2024
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Stu...
March 25, 2024
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
January 10, 2024
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 30, 2023
BeyondSpring Files 2022 Annual Report on Form 20-F
April 18, 2023
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
April 18, 2023
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lu...
March 1, 2023
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell L...
December 13, 2022
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of ...
September 13, 2022
BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
April 14, 2022
BeyondSpring Files 2021 Annual Report on Form 20-F
April 14, 2022
BeyondSpring Announces Organizational Streamlining
January 11, 2022
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
December 30, 2021
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chem...
December 15, 2021
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San ...
December 10, 2021
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemoth...
December 1, 2021
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
November 10, 2021
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Lin...
October 21, 2021
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual Inte...
October 20, 2021
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Al...
September 20, 2021